Global Intravenous Immunoglobulin (IVIg) Market to Reach $30.6 Billion by 2030
The global market for Intravenous Immunoglobulin (IVIg) estimated at US$15.6 Billion in the year 2022, is projected to reach a revised size of US$30.6 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2022-2030. IgA, one of the segments analyzed in the report, is projected to record a 10.8% CAGR and reach US$12.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the IgE segment is readjusted to a revised 7.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $4.6 Billion, While China is Forecast to Grow at 8.1% CAGR
The Intravenous Immunoglobulin (IVIg) market in the U.S. is estimated at US$4.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$5.2 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 7.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.Select Competitors (Total 24 Featured) -
- Bharat Serums and Vaccines Limited
- Biotest AG
- China Biologic Products, Inc.
- CSL Limited
- Grifols, S.A.
- Hualan Biological Engineering Inc.
- Kedrion S.p.A.
- LFB Group
- Octapharma AG
- Shanghai RAAS Blood Products Co., Ltd.
- Shire plc
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Intravenous Immunoglobulin (IVIg) - Global Key Competitors Percentage Market Share in 2023 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Intravenous Immunoglobulin (IVIg) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 3: World Historic Review for Intravenous Immunoglobulin (IVIg) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 4: World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for IgA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 6: World Historic Review for IgA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 7: World 16-Year Perspective for IgA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 8: World Recent Past, Current & Future Analysis for IgE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 9: World Historic Review for IgE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 10: World 16-Year Perspective for IgE by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for IgG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 12: World Historic Review for IgG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 13: World 16-Year Perspective for IgG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 14: World Recent Past, Current & Future Analysis for IgM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 15: World Historic Review for IgM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 16: World 16-Year Perspective for IgM by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for IgD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for IgD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for IgD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 22: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 23: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 24: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 25: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 26: World Recent Past, Current & Future Analysis for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 27: World Historic Review for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: World 16-Year Perspective for Homecare Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
UNITED STATES
- Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 29: USA Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: USA Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: USA 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 32: USA Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: USA Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: USA 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
CANADA
- Table 35: Canada Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Canada Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: Canada 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 38: Canada Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Canada Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Canada 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
JAPAN
- Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 41: Japan Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Japan Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Japan 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 44: Japan Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Japan Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: Japan 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
CHINA
- Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 47: China Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: China Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: China 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 50: China Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: China Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: China 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
EUROPE
- Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 53: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 59: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
FRANCE
- Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 62: France Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: France Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: France 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 65: France Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: France Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: France 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
GERMANY
- Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 68: Germany Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Germany Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: Germany 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 71: Germany Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Germany Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: Germany 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
ITALY
- Table 74: Italy Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Italy Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: Italy 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 77: Italy Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Italy Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: Italy 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 80: UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: UK Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: UK 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 83: UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: UK Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: UK 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
REST OF EUROPE
- Table 86: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Rest of Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: Rest of Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 89: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Rest of Europe Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Rest of Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Asia-Pacific Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Asia-Pacific 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Asia-Pacific Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Asia-Pacific 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
REST OF WORLD
- Table 98: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of World Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Rest of World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
- Table 101: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Rest of World Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 103: Rest of World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bharat Serums and Vaccines Limited
- Biotest AG
- China Biologic Products, Inc.
- CSL Limited
- Grifols, S.A.
- Hualan Biological Engineering Inc.
- Kedrion S.p.A.
- LFB Group
- Octapharma AG
- Shanghai RAAS Blood Products Co., Ltd.
- Shire plc
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 184 |
| Published | April 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 15.6 Billion |
| Forecasted Market Value ( USD | $ 30.6 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |
